Cover Image
Market Research Report
Product code 
200961

Hyperuricemia (Metabolic Disorder) - Drugs In Development, 2021

Published: | Global Markets Direct | 90 Pages | Delivery time: 1-2 business days

Price

Back to Top
Hyperuricemia (Metabolic Disorder) - Drugs In Development, 2021
Published: July 30, 2021
Global Markets Direct
Content info: 90 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Drugs In Development, 2021, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 6, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Product Code: GMDHC12975IDB

Table of Contents

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Hyperuricemia - Overview
  • Hyperuricemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hyperuricemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hyperuricemia - Companies Involved in Therapeutics Development
  • Allena Pharmaceuticals Inc
  • Arthrosi Therapeutics Inc
  • AstraZeneca Plc
  • FortuneRock (China) Ltd
  • Fuji Yakuhin Co Ltd
  • Hangzhou Grand Biologic Pharmaceutical Inc
  • Hinova Pharmaceuticals Inc
  • InventisBio Inc
  • J-Pharma Co Ltd
  • Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Nippon Chemiphar Co Ltd
  • NuBioPharma LLC
  • PegBio Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Yingli Pharmaceutical Co Ltd
  • Shanton Pharma Co Ltd
  • Stealth Biologics LLC
  • Suzhou Sinovent Pharmaceuticals Co Ltd
  • Teijin Pharma Ltd
  • Xiuzheng Pharmaceutical Group Co Ltd
  • Hyperuricemia - Drug Profiles
  • (allopurinol +verinurad) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABP-671 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ALLN-346 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • allopurinol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AR-882 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • D-0120 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • febuxostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HP-501 SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HZBio-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JPH-367 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JS-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NC-2500 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NC-2700 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PB-348 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Enzyme for Gout and Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Urate Oxidase Replacement for Acute Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAP-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SFR-9350 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SHR-4640 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • taininade - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TMX-049 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • topiroxostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • verinurad - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XNW-3009 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YL-90148 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hyperuricemia - Dormant Projects
  • Hyperuricemia - Discontinued Products
  • Hyperuricemia - Product Development Milestones
  • Featured News & Press Releases
  • Jul 12, 2021: Allena Pharmaceuticals provides update on ALLN-346 clinical development program
  • Mar 05, 2021: Shanghai Junshi Bioscience announces JS103 Injection received the acceptance notice for the investigational new drug application
  • Nov 30, 2020: Allena Pharmaceuticals announces initial data from phase 1 trial of ALLN-346
  • Sep 08, 2020: Allena Pharmaceuticals doses first subject in phase 1 clinical trial of ALLN-346, in development for the treatment of Hyperuricemia in patients with gout and advanced chronic kidney disease
  • Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase II data at the American Society of Nephrology Kidney Week 2019
  • Oct 17, 2019: Allena Pharmaceuticals to present new data on ALLN-346 at upcoming ACR/ARP Annual Meeting
  • Jul 17, 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
  • Jun 21, 2019: FDA Joint Committee recommends approval of Uloric (Febuxostat)
  • Jun 13, 2019: Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type ii diabetes in phase iia trial
  • Jan 11, 2019: Takeda Announces Outcome of FDA Advisory Committee Meeting to Review Uloric (febuxostat) Cardiovascular Outcomes Trial Results
  • Oct 22, 2018: Allena Pharmaceuticals presents preclinical data demonstrating normalized urine uric acid excretion and plasma urate reduction following treatment with ALLN-346
  • Oct 18, 2018: Allena Pharmaceuticals to present data on Kidney Disease drug candidate ALLN-346 at ACR/ARHP 2018 Annual Meeting
  • Jun 19, 2018: Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
  • Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study
  • Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development for Hyperuricemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, 2021
  • Hyperuricemia - Pipeline by Arthrosi Therapeutics Inc, 2021
  • Hyperuricemia - Pipeline by AstraZeneca Plc, 2021
  • Hyperuricemia - Pipeline by FortuneRock (China) Ltd, 2021
  • Hyperuricemia - Pipeline by Fuji Yakuhin Co Ltd, 2021
  • Hyperuricemia - Pipeline by Hangzhou Grand Biologic Pharmaceutical Inc, 2021
  • Hyperuricemia - Pipeline by Hinova Pharmaceuticals Inc, 2021
  • Hyperuricemia - Pipeline by InventisBio Inc, 2021
  • Hyperuricemia - Pipeline by J-Pharma Co Ltd, 2021
  • Hyperuricemia - Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2021
  • Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
  • Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, 2021
  • Hyperuricemia - Pipeline by NuBioPharma LLC, 2021
  • Hyperuricemia - Pipeline by PegBio Co Ltd, 2021
  • Hyperuricemia - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
  • Hyperuricemia - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, 2021
  • Hyperuricemia - Pipeline by Shanton Pharma Co Ltd, 2021
  • Hyperuricemia - Pipeline by Stealth Biologics LLC, 2021
  • Hyperuricemia - Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, 2021
  • Hyperuricemia - Pipeline by Teijin Pharma Ltd, 2021
  • Hyperuricemia - Pipeline by Xiuzheng Pharmaceutical Group Co Ltd, 2021
  • Hyperuricemia - Dormant Projects, 2021
  • Hyperuricemia - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Hyperuricemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021